Group K Diagnostics Relocates to New Laboratory, Manufacturing and Office Space in Philadelphia
News
IView-1201 Phase II IND application for the Treatment of Adenoviral Conjunctivitis Accepted by US FDA
Palvella Therapeutics Announces $10 Million in Funding from Ligand Pharmaceuticals to Accelerate PTX-022 through Phase 2/3 Clinical Study in Pachyonychia Congenita
– Fast Track-Designated Program Commencing Phase 2/3 Study in Q1 2019 –
Relmada Therapeutics Presents Clinical Data on Increased BDNF Plasma Levels in Subjects Treated with REL-1017
Findings on Effect of REL-1017 on BDNF Plasma Levels Presented at Annual Meeting of the American College of Neuropsychopharmacology
Pillo Health Launches Innovative Home Health Assistant to Dispense Medication, Track Adherence, Deliver Care Plans